Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Baxter
Moodys

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,349,840

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,349,840 protect, and when does it expire?

Patent 8,349,840 protects REXULTI and is included in one NDA.

This patent has thirty-four patent family members in twenty-eight countries.

Summary for Patent: 8,349,840
Title:Piperazine-substituted benzothiophenes for treatment of mental disorders
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001##
Inventor(s): Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:12/970,690
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,349,840
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,349,840

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-001 Jul 10, 2015 RX Yes No   Start Trial   Start Trial Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-002 Jul 10, 2015 RX Yes No   Start Trial   Start Trial Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-003 Jul 10, 2015 RX Yes No   Start Trial   Start Trial Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 RX Yes Yes   Start Trial   Start Trial Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,349,840

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-116698Apr 14, 2005

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Dow
Moodys
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.